tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matt Cross, 15 are a BUY (93.75%), 1 are a HOLD (6.25%).
Analyst Matt Cross, currently employed at ALLIANCE GLOBAL PARTNERS, carries an average stock price target met ratio of 38.89% that have a potential upside of 60.26% achieved within 262 days. Previously, Matt Cross worked at JONESTRADING.
Matt Cross’s has documented 35 price targets and ratings displayed on 8 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on SYRS, Syros Pharmaceuticals at 17-May-2022.
Analyst best performing recommendations are on VSTM (VERASTEM).
The best stock recommendation documented was for VSTM (VERASTEM) at 3/20/2020. The price target of $42 was fulfilled within 31 days with a profit of $19.56 (87.17%) receiving and performance score of 28.12.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 30-Sep-2026
$2
$0.83 (70.94%)
$2
Buy Since 04-Nov-2021
$9
$7.83 (669.23%)
$9
Buy Since 30-Oct-2020
$7
$5.17 (282.51%)
$6
11 months 25 days ago
(08-Oct-2025)
0/4 (0%)
$1.38 (24.56%)
Buy Since 28-Mar-2024
$9
$7.17 (391.80%)
1 years 1 months 25 days ago
(08-Aug-2025)
0/2 (0%)
$3.74 (71.10%)
Buy Since 03-Oct-2024
$12
$10.83 (925.64%)
$12
1 years 9 months 17 days ago
(16-Dec-2024)
3/8 (37.5%)
$6.94 (137.15%)
362
What Year was the first public recommendation made by Matt Cross?
